Last reviewed · How we verify
travatan 0.004%
travatan 0.004% is a Prostaglandin F analog Small molecule drug developed by Allergan. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension. Also known as: Travatan Z®.
Travoprost is a prostaglandin F analog that binds to prostaglandin F (FP) receptors to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.
Travatan 0.004% is a prostaglandin F2-alpha receptor agonist, classified as a small molecule drug. It is used to treat conditions such as open-angle glaucoma and ocular hypertension.
At a glance
| Generic name | travatan 0.004% |
|---|---|
| Also known as | Travatan Z® |
| Sponsor | Allergan |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F (FP) receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Travoprost mimics the action of naturally occurring prostaglandins by activating FP receptors in the eye. This activation enhances drainage of aqueous humor through the uveoscleral (unconventional) pathway, reducing intraocular pressure. The drug is administered as eye drops and is used to manage elevated intraocular pressure in glaucoma and ocular hypertension.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Foreign body sensation
Key clinical trials
- Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension (PHASE2)
- Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG) (PHASE4)
- Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG) (PHASE4)
- Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost (PHASE4)
- Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents (PHASE4)
- Effect Of Topical Prostaglandin F2α Analogs,Fractional CO2 Laser, Excimer Laser Or Their Combination In Treatment Of Vitiligo (PHASE4)
- Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients
- Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan® (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- travatan 0.004% CI brief — competitive landscape report
- travatan 0.004% updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about travatan 0.004%
What is travatan 0.004%?
How does travatan 0.004% work?
What is travatan 0.004% used for?
Who makes travatan 0.004%?
Is travatan 0.004% also known as anything else?
What drug class is travatan 0.004% in?
What development phase is travatan 0.004% in?
What are the side effects of travatan 0.004%?
What does travatan 0.004% target?
Related
- Drug class: All Prostaglandin F analog drugs
- Target: All drugs targeting Prostaglandin F (FP) receptor
- Manufacturer: Allergan — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Open-angle glaucoma
- Indication: Drugs for Ocular hypertension
- Also known as: Travatan Z®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing